Crown Laboratories Acquires Revance Therapeutics, Expanding Aesthetic Portfolio
The deal expands Crown’s presence in the aesthetics market, bringing Daxxify and the RHA Collection into its portfolio.
The deal expands Crown’s presence in the aesthetics market, bringing Daxxify and the RHA Collection into its portfolio.
The agency has accepted the resubmission seeking approval of the neuromodulator for the temporary improvement of moderate-to-severe glabellar lines and crow’s feet in adults.